Verona Pharma: In COPD, There's A Corner With Their Name On It
Verona's approval of ensifentrine in COPD offers promising potential with its MoA and safety profile in a competitive market.
腾讯网18d
郑劲平教授带您看GOLD 2025更新要点
一般而言，如有ICS使用指征，LABA+LAMA+ICS已被证明优于LABA+ICS。对于目前接受LABA+ICS的患者，需确认患者是否有既往急性加重史以及既往ICS治疗是否有效。应考虑以下因素（图3.22）： ...
Nature5y
Therapies for COPD
Inhaled corticosteroids (ICS), short- and long-acting β 2-agonists (SABA and LABA), long-acting muscarinic antagonists (LAMA) and fixed-dose combinations of LABA and ICS are the cornerstones of ...